We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

52 hedge funds and large institutions have $60.1M invested in X4 Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 9

13% more call options, than puts

Call options by funds: $271K | Put options by funds: $239K

3% more capital invested

Capital invested by funds: $58.3M → $60.1M (+$1.82M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.24% less ownership

Funds ownership: 1.9% → 1.66% (-0.24%)

7% less funds holding

Funds holding: 56 → 52 (-4)

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

Holders
52
Holders Change
-4
Holders Change %
-7.14%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
19
Reduced
9
Closed
13
Calls
$271K
Puts
$239K
Net Calls
+$32K
Net Calls Change
+$130K

Top Buyers

Rank Fund Capital Flow
1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$9.18M
2
NMC
NEA Management Company
Maryland
+$8.23M
3
CH
CVI Holdings
Delaware
+$3.76M
4
LCM
Lynwood Capital Management
Ontario, Canada
+$3.4M
5
PHP
Parkman Healthcare Partners
Connecticut
+$2.25M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.99M
2
ACM
AIGH Capital Management
Maryland
-$1.71M
3
WVP
Worth Venture Partners
New Jersey
-$428K
4
IC
Ikarian Capital
Texas
-$347K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$238K
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
51
Dimensional Fund Advisors
Texas
$59 – – –
BNP Paribas Financial Markets
52
BNP Paribas Financial Markets
France
$9 – – –
ACM
53
AIGH Capital Management
Maryland
– -$1.71M -33,257 Closed
WVP
54
Worth Venture Partners
New Jersey
– -$428K -8,338 Closed
Susquehanna International Group
55
Susquehanna International Group
Pennsylvania
– -$238K -5,020 Closed
BC
56
BIT Capital
Germany
– -$77K -1,500 Closed
KAS
57
Kestra Advisory Services
Texas
– -$56K -1,100 Closed
Connor, Clark & Lunn Investment Management (CC&L)
58
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$39K -769 Closed
PAG
59
Private Advisor Group
New Jersey
– -$23K -441 Closed
DAS
60
Dynamic Advisor Solutions
Arizona
– -$17K -337 Closed
Fidelity Investments
61
Fidelity Investments
Massachusetts
– -$17K -333 Closed
MFA
62
Mayflower Financial Advisors
Massachusetts
– -$17K -333 Closed
MLL
63
Moody Lynn & Lieberson
Massachusetts
– -$17K -333 Closed
UBS Group
64
UBS Group
Switzerland
– -$16K -318 Closed
1 2
3

XFOR Hedge Fund Activity: Q4 2022 in Review

52 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2022, worth a combined $60.1M — up 3.1% from $58.3M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of XFOR and 11 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 19 added.

The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $9.18M. The largest seller was Point72 Asset Management, cutting an estimated $2.99M.

  • 52 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2022, down from 56 in Q3 2022.
  • Funds reported $60.1M of X4 Pharmaceuticals stock for Q4 2022, up 3.1% quarter-over-quarter.
  • 11 funds opened new X4 Pharmaceuticals positions in Q4 2022 and 13 closed out, a net change of -2 holders.
  • The largest X4 Pharmaceuticals buyer in Q4 2022 was Bain Capital Life Sciences Investors, an estimated $9.18M added.
  • The largest X4 Pharmaceuticals seller in Q4 2022 was Point72 Asset Management, an estimated $2.99M sold.

Based on aggregated 13F filings for Q4 2022.